Breaking News Instant updates and real-time market news.

DIS

Disney

$112.72

0.9647 (0.86%)

, SFM

Sprouts Farmers Market

$21.82

-0.2 (-0.91%)

16:15
03/20/17
03/20
16:15
03/20/17
16:15

On The Fly: Top stock stories for Monday

The major averages started the day with a quiet opening, previewing the type of session it would be as they spent the rest of the trading day in a narrow range drifting near the unchanged line. ECONOMIC EVENTS: In the U.S., the Chicago National Activity index rose to 0.34 in February after dipping to -0.02 in January. In Europe, the U.K. said it will formally trigger its exit from the EU on March 29. Triggering Article 50 of the Lisbon Treaty, the formal procedure for leaving the bloc, will open a two-year timetable for negotiations, with Britain able to leave the EU by 2019. COMPANY NEWS: Walt Disney's (DIS) "Beauty and the Beast," the latest in a string of live-action remakes of animated classics from the company, topped box offices with a $170M launch in the U.S. alongside $180M from international markets. Shares of Disney gained 0.85% to $112.71 after the film's record-breaking debut... Shares of Sprout Farmers Market (SFM), which jumped about 25% last week, ended the day down about 0.9% at $21.83 after Bloomberg reported that Cerberus Capital-backed Albertsons has held preliminary merger talks with the company. Shares of its larger competitor Whole Foods Market (WFM) gained about 1% following the news... Snap Inc. (SNAP) landed its first Buy rating since coming public, as Monness Crespi analyst James Cakmak initiated the stock and said he is prepared to "give the benefit of the doubt" to the parent of Snapchat. The shares advanced 2% after Cakmak offered the opinion that "Snap could conceivably replace the camera app" on people's phones. MAJOR MOVERS: Among the notable gainers was Nektar Therapeutics (NKTR), which advanced over 42% after the company said that a late-stage trial of NKTR-181, which was previously granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of moderate to severe chronic pain, met the primary and secondary endpoints. Also higher was CytomX Therapeutics (CTMX), which gained 24% after announcing an expansion of the company's strategic collaboration with Bristol-Myers Squibb (BMY). Additionally, Esperion Therapeutics (ESPR) jumped 74% after the biotech company announced that the Food and Drug Administration gave feedback on its cholesterol-lowering drug, saying the bempedoic acid Phase 3 program is adequate to support approval of an LDL-C lowering indication prior to outcomes data. Among the noteworthy losers was Array Biopharma (ARRY), which fell nearly 5% after the company withdrew its FDA application for binimetinib in a rare subset of skin cancer. Also lower was Sonic (SONC), which slipped 3% Canaccord analyst Lynne Collier downgraded the stock to Hold, citing challenging industry sales, the potential for Street estimates to be too high in the midst of soft sales, a lack of upcoming catalysts, and increasing competition from non-traditional venues such as convenience stores. INDEXES: The Dow slipped 8.76, or 0.04%, to 20,905.86, the Nasdaq gained 0.53, or 0.01%, to 5,901.53, and the S&P 500 declined 4.78, or 0.2%, to 2,373.47.

DIS

Disney

$112.72

0.9647 (0.86%)

SFM

Sprouts Farmers Market

$21.82

-0.2 (-0.91%)

WFM

Whole Foods

$29.85

0.32 (1.08%)

SNAP

Snap

$19.84

0.3 (1.54%)

NKTR

Nektar

$22.10

6.6 (42.58%)

CTMX

CytomX Therapeutics

$18.89

3.71 (24.44%)

BMY

Bristol-Myers

$56.42

0.13 (0.23%)

ARRY

Array BioPharma

$10.07

-0.49 (-4.64%)

SONC

Sonic

$23.08

-0.7 (-2.94%)

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 27

    Mar

  • 28

    Mar

  • 28

    Mar

  • 29

    Mar

  • 01

    Apr

  • 27

    Apr

  • 20

    Jun

  • 30

    Jun

DIS Disney
$112.72

0.9647 (0.86%)

03/20/17
PIPR
03/20/17
NO CHANGE
Target $130
PIPR
Overweight
Disney's Beauty and the Beast topped expectations, says Piper Jaffray
Piper Jaffray analyst Stan Meyers says Disney's Beauty and the Beast topped expectations this weekend with a domestic opening of $170M, ahead of his $130M-$140M estimate and industry tracking of $125M. He now expects the film to cross the $450M mark domestically, ahead of his $400M estimate. Meyers remains a buyer of Disney shares with an Overweight rating and $130 price target.
03/16/17
PIPR
03/16/17
NO CHANGE
Target $130
PIPR
Overweight
Piper more confident after seeing Disney's Beauty and the Beast
Piper Jaffray analyst Stan Meyers says he left a screening of Disney's Beauty and the Beast more confident in his $900M global box office forecast. The analyst admits the film's 68% Rotten Tomatoes score is an issue, but he believes limited competition over the next few weeks and the film's darker undertone to broaden the target audience should secure "strong staying power" after the opening. He expects the movie to open in the $130M-$140M range. Meyers keeps an Outperform rating on Disney.
03/14/17
03/14/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Disney (DIS) upgraded to Buy from Neutral at Guggenheim with analyst Michael Morris upgraded saying that he still sees strong potential upside despite the stock's move off its lows as the company enters another expansion cycle for its film, consumer products and parks businesses. The analyst is more cautious on the Networks business, both for Disney and the broader industry, but thinks that is reflected already in Disney shares. Morris raised his price target on Disney shares to $128 from $118. 2. Dick's Sporting (DKS) upgraded to Outperform from Peer Perform at Wolfe Research. 3. Quest Diagnostics (DGX) upgraded to Conviction Buy from Buy at Goldman with analyst Isaac Ro saying the company should be a key beneficiary as the U.S. healthcare system shifts the cost burden to the individual and creates price transparency for the first time. 4. Olympic Steel (ZEUS) and Reliance Steel (RS) were upgraded to Outperform from Neutral at Macquarie, while Worthington (WOR) was upgraded to Neutral from Underperform. 5. Ethan Allen (ETH) upgraded to Strong Buy from Market Perform at Raymond James with analyst Budd Bugatch double upgrading the company saying sales comparisons get easier through 2017 while the retailer's remerchandising effort is behind it, thereby lowering the clearance markdowns. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/14/17
GUGG
03/14/17
UPGRADE
Target $128
GUGG
Buy
Disney upgraded to Buy from Neutral at Guggenheim
Guggenheim analyst Michael Morris upgraded Disney to Buy from Neutral saying that he still sees strong potential upside despite the stock's move off its lows as the company enters another expansion cycle for its film, consumer products and parks businesses. The analyst is more cautious on the Networks business, both for Disney and the broader industry, but thinks that is reflected already in Disney shares. Morris raised his price target on Disney shares to $128 from $118.
SFM Sprouts Farmers Market
$21.82

-0.2 (-0.91%)

02/27/17
RBCM
02/27/17
NO CHANGE
RBCM
Sprouts Farmers Markets fiscal 2017 guidance conservative, says RBC Capital
After Sprouts reported stronger than expected results, RBC Capital analyst William Kirk says that the company's fundamentals continue to be strong. He thinks that the company's guidance is "beatable," partly due to easing comps and lessening cannibalization, along with the contribution of the company's new stores to comp increases. Kirk remains upbeat on the company's fundamentals and keeps an Outperform rating on the shares.
03/20/17
JEFF
03/20/17
NO CHANGE
Target $22
JEFF
Buy
Jefferies sees $26/share buyout price for Sprouts Farmers Market
After Bloomberg reported that Cerberus Capital Management-backed Albertsons held preliminary talks to merge with Sprouts Farmers Market, Jefferies analyst Christopher Mandeville says historical transactions suggest a $26 per share takeout price for Sprouts. The stock in pre-market trading is up 5%, or $1.13, to $23.15. If Sprouts is willing to sell itself, multiple suitors, both financial and strategic, could show interest, leading to a competitive bidding process that could potentially push the valuation higher than $26 per share, Mandeville tells investors in a research note. The company, as one of the last few growth concepts remaining in grocery, should "receive a very healthy valuation," the analyst argues. He has a Buy rating on Sprouts with a $22 price target.
02/01/17
OTRG
02/01/17
UPGRADE
OTRG
Mixed
Sprouts Farmers Markets upgraded to Mixed from Negative at OTR Global
OTR Global changed its view on Sprouts Farmers Markets to Mixed following checks that indicate orders improved slightly in Q4 due to promotions.
02/02/17
FBCO
02/02/17
NO CHANGE
Target $23
FBCO
Outperform
Re-inflation to alleviate Sprouts Farmers Markets pressure, says Credit Suisse
Credit Suisse analyst Edward Kelly says that while short-term caution is certainly warranted given accelerating produce deflation and a tough overall competitive environment, he thinks Sprouts Farmers Markets' Q4 will eventually result in an attractive opportunity. The analyst believes the stock may be the most leveraged to re-inflation at this point, as comps should see relief when pricing firms, margin pressure should moderate as industry promotions begin to ease, and the valuation has upside given it is likely to remain a growth story. He reiterates an Outperform rating and $23 price target on the shares.
WFM Whole Foods
$29.85

0.32 (1.08%)

02/09/17
FBCO
02/09/17
NO CHANGE
Target $36
FBCO
Outperform
Whole Foods price target lowered to $36 from $40 at Credit Suisse
Credit Suisse analyst Edward Kelly lowered his price target for Whole Foods to $36 from $40 following the company's mixed Q1 earnings update. The analyst reiterates an Outperform rating on the shares as he continues to see value in the brand, believes there is a path for improved performance over time, and likes the stock's risk/reward.
02/09/17
PIVT
02/09/17
NO CHANGE
Target $20
PIVT
Sell
Pivotal calls Whole Foods sales deceleration 'alarming'
Pivotal Research analyst Ajay Jain believes Whole Foods' sales are decelerating at an "alarming rate." The company's guidance reduction last night is the latest in a multi-year string of earnings setbacks, Jain tells investors in a post-earnings research note. He keeps a Sell rating on the shares with a $20 price target.
01/20/17
01/20/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Amazon.com (AMZN) initiated with a Buy at Aegis. 2. Alphabet (GOOG, GOOGL) and Facebook (FB) were resumed with an Overweight at Pacific Crest, while Twitter (TWTR) was resumed with a Sector Weight. 3. Costco (COST) coverage was resumed with a Buy at Stifel, while Wal-Mart (WMT) and Target (TGT) were resumed with a Hold. 4. Whole Foods (WFM) was initiated with a Market Perform, while Sprouts Farmers Markets (SFM) was initiated with an Outperform at William Blair. 5. CBS (CBS) was reinstated with an Outperform at Credit Suisse. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/02/17
CLVD
02/02/17
NO CHANGE
CLVD
Whole Foods estimate lowered on softenting trends at Cleveland Research
SNAP Snap
$19.84

0.3 (1.54%)

03/20/17
03/20/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Monness Crespi analyst James Cakmak initiated Snap (SNAP) with a Buy and a $25 price target. 2. Workday (WDAY) initiated with a Buy at BofA/Merrill. 3. Berkshire Hathaway (BRK.A) initiated with an Equal Weight at Morgan Stanley. 4. MeetMe (MEET) initiated with a Buy at Canaccord. 5. ARC Document (ARC) resumed with a Buy at B. Riley. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/17/17
03/17/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Netflix (NFLX) initiated with an Outperform at Bernstein. 2. Snap (SNAP) initiated with a Neutral at Mizuho. 3. Cantel Medical (CMD) initiated with a Market Perform at Raymond James. 4. Hilton (HLT) reinstated with an Overweight at JPMorgan. 5. Regeneron (REGN) initiated with a Perform at Oppenheimer. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/20/17
MONN
03/20/17
INITIATION
Target $25
MONN
Buy
Snap initiated with a Buy at Monness Crespi
Monness Crespi analyst James Cakmak initiated Snap with a Buy and a $25 price target.
03/17/17
MZHO
03/17/17
INITIATION
Target $20
MZHO
Neutral
Snap initiated with a Neutral at Mizuho
Mizuho analyst Neil Doshi started Snap Inc. with a Neutral rating and $20 price target.
NKTR Nektar
$22.10

6.6 (42.58%)

03/20/17
ROTH
03/20/17
NO CHANGE
Target $31
ROTH
Buy
Roth Capital raises Nektar price target to $31 after 'impressive' opioid data
Roth Capital analyst Michael Higgins called Nektar's Phase 3 results for NKTR-181 "impressive" and said he expect management will now enter into negotiations to out-license the drug while meeting with the FDA. Higgins, who believes the drug is worth $2B by "conservatively" estimating its value at 3-4X peak sales, raised his price target on Nektar shares to $31 from $23 and reiterates a Buy rating on the stock.
01/06/17
BTIG
01/06/17
INITIATION
Target $22
BTIG
Buy
Nektar initiated with a Buy at BTIG
BTIG analyst Robert Hazlett started Nektar Therapeutics with a Buy rating and $22 price target. Several "intriguing" emerging therapeutics along with multiple near-term catalysts make the shares attractive, Hazlett tells investors in a research note.
01/26/17
PIPR
01/26/17
NO CHANGE
PIPR
Overweight
Celgene acquisition highlights underappreciated Nektar asset, says Piper Jaffray
After Celgene (CELG) announced this morning a deal to acquire Delinia for $300M plus up to $475M in potential milestones, Piper Jaffray analyst Joshua Schimmer noted that the company's lead asset, DEL106, being developed for autoimmune disorders, is similar to Nektar's (NKTR) NKTR-358. While many investors are familiar with Nektar's immune-oncology program, NKTR-214, far fewer are familiar with NKTR-358, though both represent potential blockbuster opportunities if successful, Schimmer tells investors. He keeps an Overweight rating on Nektar, which he identifies as one of his top mid-cap picks.
03/20/17
PIPR
03/20/17
NO CHANGE
Target $29
PIPR
Overweight
Nektar price target raised to $29 after opioid trial success at Piper Jaffray
Piper Jaffray analyst Joshua Schimmer said he thought prospects of success for NKTR-181 were very low after a failed Phase 2 study but he was "happy to be proven wrong" after the SUMMIT trial succeeded. A human abuse liability study will read-out around mid-2017, after which the company will meet with the FDA to discuss whether the package for NKTR-181 is adequate for filing, Schimmer noted. He raised his price target on Nektar shares to $29 from $25 and keeps an Overweight rating on the stock, which he calls his "top mid-cap biotech stocks for other reasons," such as its multiple royalty streams from partnered products and its emerging immuno-oncology platform.
CTMX CytomX Therapeutics
$18.89

3.71 (24.44%)

01/03/17
OPCO
01/03/17
DOWNGRADE
OPCO
Perform
CytomX Therapeutics downgraded to Perform from Outperform at Oppenheimer
Oppenheimer analyst Leah Rush Cann downgraded CytomX Therapeutics to Perform citing valuation. The analyst's model assumes only one of the company's experimental therapies has a revenue impact between 2016 and 2025.
03/20/17
NOMU
03/20/17
NO CHANGE
Target $32
NOMU
Buy
CytomX Therapeutics price target raised to $32 from $21 at Nomura
03/01/17
NOMU
03/01/17
INITIATION
Target $21
NOMU
Buy
CytomX Therapeutics initiated with a Buy at Nomura
Nomura initiated CytomX Therapeutics with a Buy and a $21 price target.
03/20/17
BOFA
03/20/17
NO CHANGE
Target $28
BOFA
Buy
CytomX Therapeutics price target raised to $28 from $23 at BofA/Merrill
BofA/Merrill raised CytomX Therapeutics' (CTMX) price target to $28 to reflect expansion of the Bristol-Myers (BMY) collaboration and payments.
BMY Bristol-Myers
$56.42

0.13 (0.23%)

03/06/17
FBCO
03/06/17
NO CHANGE
FBCO
Near-Term acquisition of Bristol-Myers unlikely, says Credit Suisse
Credit Suisse analyst Vamil Divan says there is increasing investor focus on strategic actions and opportunities around Bristol-Myers (BMY) following the company's recent stumbles and the increased stake activist investors have taken in the stock. The analyst notes that "the big question" remains whether any of its peers may be interested in an outright acquisition, with Pfizer (PFE), Novartis (NVS) and Gilead (GILD) among the possible acquirers. While the numbers may make sense, Divan sees an acquisition in the next 9-12 months as unlikely as he needs more clarity on some of the large unknowns in the lung cancer market and macro issues such as corporate tax reform.
02/15/17
DBAB
02/15/17
NO CHANGE
DBAB
Deutsche not seeing Pfizer buying Bristol-Myers at this time
Following yesterday's speculation of a potential deal, Deutsche Bank analyst Gregg Gilbert said he would be surprised to see Pfizer (PFE) make a move on Bristol-Myers Squibb (BMY) at this stage. Such an acquisition "would represent a very large and concentrated opportunity/risk on immuno-oncology, an area fraught with near-term uncertainty," Gilbert told investors last night in a research note. He believes that if Pfizer were to use $90B for a deal, it would prefer to acquire a more diverse set of value drivers. The analyst keeps a Hold rating on Bristol and Buy rating on Pfizer. Bristol shares rose 3% yesterday to $53.71 amid speculation of a potential takeover. The conjecture had Roche (RHHBY), Novartis (NVS) and Pfizer potentially looking into a bid for Bristol.
02/01/17
GSCO
02/01/17
NO CHANGE
GSCO
Bristol-Myers estimates trimmed for Sprycel loss at Goldman
Goldman reduced Bristol-Myers earnings estimates by 4c-7c for 2017-2021 to reflect the lost of the Sprycel appeal in the EU. The firm continues to rate Bristol-Myers a Buy.
03/08/17
PIPR
03/08/17
NO CHANGE
Target $60
PIPR
Neutral
Piper views near-term takeout of Bristol-Myers as unlikely
In a research note titled "Lung Data to Define Value....Not M&A Talk," Piper Jaffray analyst Richard Purkiss contends that news reports suggesting Bristol-Myers (BMY) is a takeover target are "wide of the mark." Industry buyers are unlikely to show interest ahead of the immuno-oncology data readouts in the next 12 months, Purkiss tells investors. He believes the key value-defining events for Bristol over the next year are the four large I/O Combo studies set to read out from mid-2017: AstraZeneca's (AZN) MYSTIC, Merck's (MRK) KN-189, Roche's (RHHBY) IMpower 150 and the company's own CheckMate-227. Ahead of these data, it is virtually impossible to assign a stable fair value to Bristol's I/O franchise, Purkiss argues. He believes investors seeking to benefit from industry consolidation in the near-term should own small- or mid-cap oncology companies. The analyst has a Neutral rating on Bristol with a $60 price target. The stock closed yesterday down 64c to $56.33.
ARRY Array BioPharma
$10.07

-0.49 (-4.64%)

03/20/17
COWN
03/20/17
NO CHANGE
Target $14
COWN
Outperform
Array BioPharma weakness a buying opportunity, says Cowen
Cowen analyst Chris Shibutani said Array's decision to withdraw its application for binimetinib monotherapy for the treatment of NRAS-mutant melanoma was prudent given the known modest efficacy benefit. He views the decision as a de-risking event and said weakness in the shares is a buying opportunity. Shibutani reiterated his Outperform rating and lowered his price target to $14 from $15 on Array Biopharma shares.
03/20/17
LEER
03/20/17
NO CHANGE
Target $9
LEER
Market Perform
Binimetinib NDA withdrawal 'a clear setback' for Array BioPharma, says Leerink
Leerink analyst Michael Schmidt notes that Array BioPharma announced it has withdrawn its new drug application for binimetinib in NRAS+ melanoma following recent FDA interactions since results of the Phase 3 trial do not support regulatory approval. While NRAS+ melanoma was only a small value driver for the company, the analyst thinks this comes as a surprise to investors and is "a clear setback" for Array and management's regulatory and commercial strategy. He reiterated a Market Perform rating on the stock, and lowered his price target on the shares to $9 from $11.
03/20/17
WELS
03/20/17
NO CHANGE
WELS
Array chances in BRAF not impacted by NRAS melanoma withdrawal, says Wells Fargo
After Array BioPharma withdrew its application for FDA approval of its binimetinib drug as an NRAS mutant melanoma treatment following a meeting with the agency, Wells Fargo does not think the withdrawal impacts the chances of the drug succeeding as a treatment for BRAF melanoma. Wells says that the BRAF indication is larger, while the benefit of the drug is also greater in that indication and it appears to be best in class. Wells trimmed its price target on Array to $13-$15 from $16-$18 but keeps an Outperform rating on the shares.
03/20/17
JPMS
03/20/17
NO CHANGE
Target $9
JPMS
Neutral
JPMorgan sees Array down 5%-10% on withdrawal news
JPMorgan analyst Anupam Rama says Array BioPharma's withdrawal of its new drug application filing for binimetinib in NRAS melanoma is a surprise. The analyst lowered his price target for the shares to $9 from $10 and thinks the stock today could be down 5%-10%. The analyst notes that NRAS melanoma only contributed around $100M in peak sales and $1 per share to his model. Rama keeps a Neutral rating on Array. The stock in premarket trading is down 14%, or $1.41, to $9.15.
SONC Sonic
$23.08

-0.7 (-2.94%)

03/20/17
ADAM
03/20/17
DOWNGRADE
Target $24
ADAM
Hold
Sonic downgraded to Hold at Canaccord
As reported previously, Canaccord analyst Lynne Collier downgraded Sonic to Hold from Buy. Collier cited challenging industry sales, the potential for Street estimates to be too high in the midst of soft sales, a lack of upcoming catalysts, and increasing competition from non-traditional venues such as convenience stores. Collier lowered her price target to $24 from $30 on Sonic shares.
03/20/17
03/20/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Pivotal Research analyst Brian Wieser downgraded Alphabet (GOOGL) to Hold from Buy citing brand safety concerns and valuation following the recent rally in the shares. News last week that Havas, the sixth largest global media network, is pulling its spending from Google's YouTube and Google Display Network in the U.K. because Google was "unable to provide specific reassurances, policy and guarantees that their video or display content is classified either quickly enough or with the correct filters" is a big deal, Wieser tells investors. 2. Canaccord analyst Lynne Collier downgraded Sonic (SONC) to Hold from Buy, citing challenging industry sales, the potential for Street estimates to be too high in the midst of soft sales, a lack of upcoming catalysts, and increasing competition from non-traditional venues such as convenience stores. 3. Piper Jaffray analyst Alexander Potter downgraded Mobileye (MBLY) to Neutral saying that while demanding a higher buyout price may be justified, he "begrudgingly" concluded that the price Intel (INTC) is paying for the company is fair. The analyst raised his price target for Mobileye shares to $63.54 from $60 to reflect Intel's offer. 4. Susquehanna analyst Sam Poser downgraded Caleres (CAL) citing the company's "disappointing" results and his belief that the company will not be able to overcome industry headwinds. 5. Goldman Sachs analyst Conor Fitzgerald downgraded Stifel Financial (SF) to Neutral from Buy while raising his price target for the shares to $59 from $58. The analyst believes LPL Financial (LPLA), a stock he upgraded this morning to Conviction Buy, offers more upside at current valuations. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/14/16
12/14/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Dunkin' Brands (DNKN) initiated with a Market Perform at Cowen. 2. Sonic (SONC) initiated with a Market Perform at Cowen. 3. Advance Auto Parts (AAP) was initiated with an Overweight at Atlantic Equities while the firm initiated AutoZone (AZO), Genuine Parts (GPC), and O'Reilly Automotive (ORLY) with a Neutral. 4. Blackhawk (HAWK) initiated with a Buy at Craig-Hallum. 5. Evercore Partners (EVR) initiated with a Neutral at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/16/16
MSCN
12/16/16
INITIATION
MSCN
Sonic coverage initiated at MScience

TODAY'S FREE FLY STORIES

RETA

Reata Pharmaceuticals

$32.06

-0.46 (-1.41%)

22:11
07/26/17
07/26
22:11
07/26/17
22:11
Syndicate
Reata Pharmaceuticals 3.25M share Secondary priced at $31.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Jul

SNNA

Sienna Biopharmaceuticals

22:03
07/26/17
07/26
22:03
07/26/17
22:03
Syndicate
Sienna Biopharmaceuticals 4.3M share IPO priced at $15.00 »

The deal priced between…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

PG

Procter & Gamble

$89.30

0.16 (0.18%)

, BUD

AB InBev

$115.71

1.75 (1.54%)

20:25
07/26/17
07/26
20:25
07/26/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

PG

Procter & Gamble

$89.30

0.16 (0.18%)

BUD

AB InBev

$115.71

1.75 (1.54%)

CMCSA

Comcast

$39.35

-0.4 (-1.01%)

CMCSK

Comcast

VZ

Verizon

$44.40

0.42 (0.95%)

MO

Altria Group

$71.73

-0.51 (-0.71%)

CELG

Celgene

$137.75

1.31 (0.96%)

CHTR

Charter

$348.77

0.77 (0.22%)

UPS

UPS

$112.29

-0.93 (-0.82%)

BMY

Bristol-Myers

$55.98

0.03 (0.05%)

DOW

Dow Chemical

$66.42

-0.43 (-0.64%)

COP

ConocoPhillips

$43.70

0.05 (0.11%)

RTN

Raytheon

$168.88

-0.71 (-0.42%)

ADP

ADP

$105.98

2.8 (2.71%)

JCI

Johnson Controls

$43.32

-0.86 (-1.95%)

LUV

Southwest

$59.52

0.7 (1.19%)

MCK

McKesson

$166.35

-1.28 (-0.76%)

PCG

PG&E

$67.90

0.39 (0.58%)

VLO

Valero

$67.99

-0.45 (-0.66%)

ALXN

Alexion

$131.07

1.72 (1.33%)

ZBH

Zimmer Biomet

$128.70

-0.07 (-0.05%)

MGM

MGM Resorts

$33.87

-0.4 (-1.17%)

DPS

Dr Pepper Snapple

$92.15

0.26 (0.28%)

KKR

KKR

$19.31

-0.15 (-0.77%)

TWTR

Twitter

$19.61

-0.36 (-1.80%)

LLL

L3 Technologies

$175.52

-1.79 (-1.01%)

NLSN

Nielsen

$39.89

1.27 (3.29%)

DNKN

Dunkin' Brands

$52.52

-0.71 (-1.33%)

WIX

Wix.com

$76.85

0.9 (1.19%)

TREE

LendingTree

$183.80

-2.25 (-1.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 27

    Jul

  • 27

    Jul

  • 27

    Jul

  • 27

    Jul

  • 27

    Jul

  • 27

    Jul

  • 27

    Jul

  • 27

    Jul

  • 27

    Jul

  • 27

    Jul

  • 27

    Jul

  • 27

    Jul

  • 27

    Jul

  • 27

    Jul

  • 27

    Jul

  • 27

    Jul

  • 27

    Jul

  • 27

    Jul

  • 27

    Jul

  • 27

    Jul

  • 27

    Jul

  • 27

    Jul

  • 27

    Jul

  • 27

    Jul

  • 27

    Jul

  • 27

    Jul

  • 30

    Jul

  • 02

    Aug

  • 06

    Aug

  • 07

    Aug

  • 07

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 10

    Aug

  • 14

    Aug

  • 21

    Aug

  • 29

    Aug

  • 30

    Aug

  • 11

    Sep

  • 13

    Sep

  • 19

    Sep

  • 20

    Sep

  • 21

    Sep

  • 24

    Sep

  • 23

    Oct

  • 09

    Nov

  • 05

    Mar

DISCA

Discovery

$26.58

0.65 (2.51%)

, SNI

Scripps Networks

$84.07

2.62 (3.22%)

19:33
07/26/17
07/26
19:33
07/26/17
19:33
Periodicals
Discovery in lead to buy Scripps, Reuters says »

Discovery (DISCA) has…

DISCA

Discovery

$26.58

0.65 (2.51%)

SNI

Scripps Networks

$84.07

2.62 (3.22%)

VIA

Viacom

$39.75

-0.6 (-1.49%)

VIAB

Viacom

$34.37

-0.64 (-1.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

  • 09

    Aug

VIA

Viacom

$39.75

-0.6 (-1.49%)

, VIAB

Viacom

$34.37

-0.64 (-1.83%)

19:30
07/26/17
07/26
19:30
07/26/17
19:30
Periodicals
Breaking Periodicals news story on Viacom, Viacom »

Viacom drops bidding for…

VIA

Viacom

$39.75

-0.6 (-1.49%)

VIAB

Viacom

$34.37

-0.64 (-1.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

DISCA

Discovery

$26.58

0.65 (2.51%)

, SNI

Scripps Networks

$84.07

2.62 (3.22%)

19:28
07/26/17
07/26
19:28
07/26/17
19:28
Periodicals
Discovery offer for Scripps deemed superior to Viacom's, CNBC's Faber says »

Scripps (SNI) will enter…

DISCA

Discovery

$26.58

0.65 (2.51%)

SNI

Scripps Networks

$84.07

2.62 (3.22%)

VIA

Viacom

$39.75

-0.6 (-1.49%)

VIAB

Viacom

$34.37

-0.64 (-1.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

  • 09

    Aug

CRAY

Cray

$18.60

-0.3 (-1.59%)

, STX

Seagate

$32.34

-0.86 (-2.59%)

19:18
07/26/17
07/26
19:18
07/26/17
19:18
Hot Stocks
Cray, Seagate enter partnership centered around ClusterStor »

Cray (CRAY) announced it…

CRAY

Cray

$18.60

-0.3 (-1.59%)

STX

Seagate

$32.34

-0.86 (-2.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

MDXG

MiMedx

$14.65

-0.22 (-1.48%)

19:18
07/26/17
07/26
19:18
07/26/17
19:18
Earnings
MiMedx backs FY17 adjusted EPS view of 31c-33c, consensus 30c »

Raises FY17 revenue view…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 13

    Nov

  • 14

    Nov

MDXG

MiMedx

$14.65

-0.22 (-1.48%)

19:17
07/26/17
07/26
19:17
07/26/17
19:17
Earnings
Breaking Earnings news story on MiMedx »

MiMedx sees Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 13

    Nov

  • 14

    Nov

MDXG

MiMedx

$14.65

-0.22 (-1.48%)

19:16
07/26/17
07/26
19:16
07/26/17
19:16
Earnings
MiMedx reports Q2 EPS 7c, consensus 7c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 13

    Nov

  • 14

    Nov

GE

General Electric

$25.59

0.15 (0.59%)

, AEP

American Electric

$69.45

0.61 (0.89%)

19:08
07/26/17
07/26
19:08
07/26/17
19:08
Hot Stocks
Invenergy, GE to build 2,000 megawatt wind farm in Oklahoma »

Invenergy, along with GE…

GE

General Electric

$25.59

0.15 (0.59%)

AEP

American Electric

$69.45

0.61 (0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 02

    Oct

PSA

Public Storage

$210.06

2.34 (1.13%)

19:05
07/26/17
07/26
19:05
07/26/17
19:05
Earnings
Pure Storage reports Q2 core FFO $2.51, consensus $2.54 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

BRK.A

Berkshire Hathaway

$259,600.00

189.98 (0.07%)

, BRK.B

Berkshire Hathaway

$173.02

0.08 (0.05%)

18:57
07/26/17
07/26
18:57
07/26/17
18:57
Periodicals
Breaking Periodicals news story on Berkshire Hathaway, Berkshire Hathaway »

Elliott wins short delay…

BRK.A

Berkshire Hathaway

$259,600.00

189.98 (0.07%)

BRK.B

Berkshire Hathaway

$173.02

0.08 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXTI

AXT, Inc.

$7.60

0.25 (3.40%)

18:43
07/26/17
07/26
18:43
07/26/17
18:43
Earnings
AXT, Inc. sees Q3 EPS 8c-10c, consensus 7c »

Sees Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 03

    Aug

  • 10

    Aug

  • 19

    Sep

NGD

New Gold

$3.17

0.15 (4.97%)

18:42
07/26/17
07/26
18:42
07/26/17
18:42
Hot Stocks
New Gold names Paula Myson as CFO »

Myson has over 25 years…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

NGD

New Gold

$3.17

0.15 (4.97%)

18:40
07/26/17
07/26
18:40
07/26/17
18:40
Earnings
New Gold reports Q2 adjusted EPS 2c, consensus 2c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

PKG

Packaging Corp.

$108.80

0.22 (0.20%)

18:37
07/26/17
07/26
18:37
07/26/17
18:37
Earnings
Packaging Corp. sees Q3 EPS $1.68, consensus $1.66 »

Looking ahead to the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 12

    Sep

PKG

Packaging Corp.

$108.80

0.22 (0.20%)

18:36
07/26/17
07/26
18:36
07/26/17
18:36
Earnings
Packaging Corp. reports Q2 adjusted EPS $1.52, consensus $1.47 »

Reports Q2 revenue $1.6B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 12

    Sep

CUBI

Customers Bancorp

$28.24

-0.25 (-0.88%)

18:31
07/26/17
07/26
18:31
07/26/17
18:31
Hot Stocks
Customers Bank expands private, commercial banking unit into Chicago »

Customers Bank announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

HNHPF

Hon Hai Precision

$7.70

-0.02 (-0.26%)

18:21
07/26/17
07/26
18:21
07/26/17
18:21
Hot Stocks
White House welcomes Foxconn announcement of LCD panel plant in Wisconsin »

President Donald J. Trump…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFBK

Northfield Bancorp

$16.69

-0.34 (-2.00%)

18:15
07/26/17
07/26
18:15
07/26/17
18:15
Earnings
Northfield Bancorp reports Q2 EPS 18c, consensus 16c »

Net interest income for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

TXN

Texas Instruments

$82.53

1.14 (1.40%)

18:10
07/26/17
07/26
18:10
07/26/17
18:10
Periodicals
Texas Instruments' strong results, outlook signal further upside, Barron's says »

Texas Instruments…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

FIBK

First Interstate

$36.55

-0.7 (-1.88%)

18:09
07/26/17
07/26
18:09
07/26/17
18:09
Earnings
First Interstate reports Q2 core EPS 59c, consensus 56c »

The company's net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

ISTR

Investar Holding

$23.05

0.05 (0.22%)

18:03
07/26/17
07/26
18:03
07/26/17
18:03
Earnings
Investar Holding reports Q2 EPS 22c, consensus 23c »

Net interest income for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HUBG

Hub Group

$39.80

-0.5 (-1.24%)

17:58
07/26/17
07/26
17:58
07/26/17
17:58
Hot Stocks
Hub Group sees FY17 gross margin 10.9%-11.3% »

Hub Group sees high…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.